Interview with Jonathan Zhu, General Manager, Celgene China
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Address: No. 222, Huangpu District, Shanghai Yan’an East Road
, Bund Center, 1102 – Room 1104
Zip: 200002 ,China
Tel: +86 216 133 9333
The new base is committed to providing innovative medicines that can really change the life for patients. Our mission is to build a global enterprise based biopharmaceutical, while focusing on the exploration, development, and commercialization of pharmaceutical products for the treatment of cancer and other serious diseases such as immune and inflammatory.
Major medical centers about 300 a number of new base compounds of clinical trials. Compounds of these studies are for blood and solid tumor cancer patients suffering from an incurable research, including multiple myeloma, bone marrow hyperplasia anomaly syndrome, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL ), myelofibrosis, small cell lung cancer and prostate cancer.
As committed to the clinical achievements, we are equally committed to providing patient support, which is the guiding principle of the new base. We believe that all patients should be given the opportunity to benefit from our research. New base by the industry-leading program patients were placed in the first, to provide information, support, and our innovative therapies.
Revlimid
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Could you please give a brief introduction to the ABO and its history? ABO was established in 2005. The CRO business emerged in 2000 in China, and provided services for…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company Xian-Janssen and then in the China National Pharmaceutical Group. Could you highlight the…
You have been here in China for about a year. What were your assumptions about China before you arrived and were things more or less what you thought they would…
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Liam Condon, Managing Director of Bayer Healthcare China discusses the government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s…
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this…
You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely…
BioSino has experienced many changes since it was first established and has taken on many different forms and functions. Can you provide a brief history of the company and the…
See our Cookie Privacy Policy Here
